Page 130 - Read Online

Page 785 Wong et al. Cancer Drug Resist 2023;6:768-87 https://dx.doi.org/10.20517/cdr.2023.58

81. Zou X, Li X, Ke H, et al. Prognostic value of neoantigen load in immune checkpoint inhibitor therapy for cancer. Front Immunol
2021;12:689076. DOI
82. Ma W, Pham B, Li T. Cancer neoantigens as potential targets for immunotherapy. Clin Exp Metastasis 2022;39:51-60. DOI
83. Schumacher TN, Scheper W, Kvistborg P. Cancer neoantigens. Annu Rev Immunol 2019;37:173-200. DOI
84. Gerber HP, Sapra P, Loganzo F, May C. Combining antibody-drug conjugates and immune-mediated cancer therapy: what to
expect? Biochem Pharmacol 2016;102:1-6. DOI
85. Ferraro E, Drago JZ, Modi S. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and
future directions. Breast Cancer Res 2021;23:84. DOI
86. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive
metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 2023;401:105-17.
DOI
87. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med
2022;387:9-20. DOI
88. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med
2021;384:1529-41. DOI
89. Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal
growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
Lancet 2023;402:1423-33. DOI
90. Schmid P, Im SA, Armstrong A, et al. BEGONIA: phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic
triple-negative breast cancer (TNBC) - Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd). J
Clin Oncol 2021;39:1023. DOI
91. Schmid P, Jung KH, Wysocki PJ, et al. 166MO datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment
for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): initial results from BEGONIA, a phase Ib/II
study. Ann Oncol 2022;33:S199. DOI
92. Franzese O, Graziani G. Role of PARP inhibitors in cancer immunotherapy: potential friends to immune activating molecules and
foes to immune checkpoints. Cancers 2022;14:5633. DOI
93. Peyraud F, Italiano A. Combined PARP inhibition and immune checkpoint therapy in solid tumors. Cancers 2020;12:1502. DOI
+
94. Pantelidou C, Sonzogni O, De Oliverira Taveira M, et al. PARP inhibitor efficacy depends on CD8 T-cell recruitment via intratumoral
STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov 2019;9:722-37. DOI
95. Ding L, Chen X, Xu X, et al. PARP1 suppresses the transcription of PD-L1 by poly(ADP-ribosyl)ating STAT3. Cancer Immunol Res
2019;7:136-49. DOI
96. Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of
advanced or metastatic triple-negative breast cancer. JAMA Oncol 2019;5:1132-40. DOI
97. Domchek SM, Postel-Vinay S, Im SA, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast
cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol 2020;21:1155-64. DOI
98. Sammons SL, Tan TJ, Im YH, et al. DORA: a phase II, multicenter, international study of olaparib with or without durvalumab as a
chemotherapy-free maintenance strategy in platinum-pretreated advanced triple-negative breast cancer (TNBC). Available from:
https://www.tempus.com/wp-content/uploads/2022/12/Sammons_DORA_Poster_SABCS2022-.pdf. [Last accessed on 15 Nov
2023].
99. Yap TA, Bardia A, Dvorkin M, et al. Avelumab plus talazoparib in patients with advanced solid tumors: the JAVELIN PARP medley
nonrandomized controlled trial. JAMA Oncol 2023;9:40-50. DOI
100. Schram AM, Colombo N, Arrowsmith E, et al. Avelumab plus talazoparib in patients with BRCA1/2- or ATM-altered advanced solid
tumors: results from JAVELIN BRCA/ATM, an open-label, multicenter, phase 2b, tumor-agnostic trial. JAMA Oncol 2023;9:29-39.
DOI
101. Zhang Q, Shao B, Tong Z, et al. A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with
recurrent or metastatic triple-negative breast cancer. BMC Med 2022;20:321. DOI
102. Vitale M, Rezzani R, Rodella L, et al. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2)
down-regulation in high-grade primary breast carcinoma lesions. Cancer Res 1998;58:737-42. PubMed
103. Henle AM, Nassar A, Puglisi-Knutson D, Youssef B, Knutson KL. Downregulation of TAP1 and TAP2 in early stage breast cancer.
PLoS One 2017;12:e0187323. DOI
104. Pedersen MH, Hood BL, Beck HC, Conrads TP, Ditzel HJ, Leth-Larsen R. Downregulation of antigen presentation-associated
pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors. Oncoimmunology 2017;6:e1305531. DOI
105. Garrido MA, Rodriguez T, Zinchenko S, et al. HLA class I alterations in breast carcinoma are associated with a high frequency of the
loss of heterozygosity at chromosomes 6 and 15. Immunogenetics 2018;70:647-59. DOI
106. Nomura T, Huang WC, Zhau HE, Josson S, Mimata H, Chung LWK. β2-microglobulin-mediated signaling as a target for cancer
therapy. Anticancer Agents Med Chem 2014;14:343-52. DOI
107. Luo N, Nixon MJ, Gonzalez-Ericsson PI, et al. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T
lymphocyte responses in breast cancer. Nat Commun 2018;9:248. DOI
108. Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of resistance to immune checkpoint blockade: why